Navigating Paramount Health Care Skyrizi Prior Authorization
Klivira simplifies the Paramount Health Care Skyrizi prior authorization process, enabling your team to manage complex requirements efficiently and reduce administrative burden.
For revenue cycle directors and prior authorization coordinators, managing specialty drug approvals like Skyrizi under Paramount Health Care's benefit design presents unique challenges. Understanding the specific formulary placement, step therapy protocols, and documentation requirements is critical to securing timely approvals and optimizing patient access to essential IL-23 inhibitor therapy.
Paramount Health Care Formulary Placement for Skyrizi (Risankizumab)
Skyrizi, an IL-23 inhibitor indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, is typically positioned on Paramount Health Care's specialty drug tier. This placement mandates a comprehensive prior authorization submission, adhering to the payer's clinical criteria and formulary management policies, often dictated by their pharmacy benefit manager.
Prior Authorization Requirements and Step Therapy Protocols
Paramount Health Care's prior authorization for Skyrizi commonly involves specific step-therapy requirements. Patients may need to demonstrate inadequate response or contraindication to preferred conventional systemic therapies or other biologics before risankizumab is approved. Thorough documentation of diagnosis, previous treatments, and clinical rationale is crucial.
Navigating Quantity Limits and Specialty Pharmacy Dispensing
Consistent with high-cost biologics, Paramount Health Care typically imposes quantity limits on Skyrizi prescriptions, often restricting dispensing to a 30-day supply. Furthermore, dispensing is routinely routed through designated specialty pharmacies, which manage distribution, patient support programs, and adherence monitoring for these complex medications.
Expediting Paramount Health Care Skyrizi ePA Submissions
Submitting prior authorizations for Skyrizi to Paramount Health Care requires precise adherence to their specific forms and clinical review criteria. Leveraging electronic prior authorization (ePA) platforms, such as Klivira, can significantly streamline the X12 278 transaction and attachment of supporting clinical documentation, accelerating payer review and decision-making.
Optimizing Paramount Health Care Skyrizi PA Workflows with Klivira
Klivira automates the data extraction and submission for Paramount Health Care Skyrizi prior authorization requests directly from your EMR, reducing manual effort and potential errors. Our platform ensures submissions are complete and compliant with payer-specific guidelines, improving approval rates and patient access to essential therapy.
Frequently asked questions
What is the typical formulary tier for Skyrizi under Paramount Health Care?
Skyrizi, as a specialty biologic, is generally placed on Paramount Health Care's highest formulary tier (e.g., Tier 4 or 5). This designation means it requires prior authorization and may have higher patient cost-sharing responsibilities, aligning with their PBM's formulary design.
Does Paramount Health Care require step therapy for Skyrizi?
Yes, Paramount Health Care typically implements step therapy protocols for Skyrizi. This often requires documentation of a trial and failure or contraindication to less costly or preferred alternative therapies before approval for risankizumab, reflecting common clinical guidelines for IL-23 inhibitors.
How does Klivira assist with Paramount Health Care Skyrizi PA submissions?
Klivira automates the prior authorization workflow for Paramount Health Care Skyrizi by integrating with your EMR, extracting relevant patient data, and populating payer-specific forms. This reduces manual data entry, minimizes errors, and facilitates faster ePA submissions, enhancing operational efficiency.
What documentation is crucial for a Paramount Health Care Skyrizi PA?
Essential documentation includes the patient's confirmed diagnosis (e.g., plaque psoriasis, psoriatic arthritis, Crohn's disease), a comprehensive history of failed or contraindicated prior treatments, current lab results, and the prescribing physician's clinical rationale for selecting Skyrizi.
Is Skyrizi dispensed by a specialty pharmacy for Paramount Health Care members?
Yes, Skyrizi, like most high-cost specialty biologics, is typically dispensed exclusively through Paramount Health Care's contracted specialty pharmacy network. These pharmacies provide specialized handling, patient education, and adherence support programs.
How can Klivira improve turnaround times for Skyrizi PAs with Paramount Health Care?
By automating data extraction and ensuring complete, accurate ePA submissions, Klivira significantly reduces the administrative burden and potential for delays caused by incomplete documentation. This efficiency helps accelerate the review process by Paramount Health Care, leading to faster approval decisions.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo